Erratum: SH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis

There is an error in a figure published in the article by Tzouvelekis and colleagues (1) that appeared in the February 15, 2017, issue of the *Journal*. In Figure 3A, the two small boxes on the top left explaining the color coding used in the bar graph were inadvertently reversed because of a printer's error. The box labeled 0 (hours) should be gray and the box labeled 24 (hours) should be black. For the convenience of our readers, we have reproduced the correct version of Figure 3 in its entirety. ■



Figure 3. SH2 domain–containing phosphatase-2 (SHP2) negatively regulates fibroblast proliferation and survival *in vitro*. (*A*) Normal human lung fibroblasts (NHLFs) were stimulated with platelet-derived growth factor (PDGF)-BB (25 ng/ml) for 6 hours. PDGF-BB stimulation induced a significant increase (2.7-fold) in proliferation rates of mock- and inactive SHP2 (R465M)-treated cells compared with unstimulated cells. Transfection with active SHP2 (wild-type [WT] and E76A) led to a significant decrease in PDGF-BB–induced proliferation (1.2-fold) compared with mock- or R465M-treated cells. Each *bar* represents mean expression of six NHLF samples (biological replicates). Data (ratio of 24 h [*black bar portion*] to 0 h [*gray bar portion*], absorbance) represent means ± SD. One-way analysis of variance (ANOVA), $*P < 0.05$. (*B*) NHLFs were treated with the indicated plasmids without growth factor stimulation, and cells were harvested 24 hours afterward for RNA extraction. Shown is the relative change in SHP2, caspase-3 (CASP3), and B-cell CLL/lymphoma 2 (BCL2) mRNA levels. Each *bar and error bar* represents the mean ± SD expression of four samples (biological replicates). *Bars* are shown for the relative changes (fold) by setting the indicated control level to 1.0. One-way ANOVA, $*P < 0.05$. (*C*) NHLFs were treated with the indicated plasmids, and cells were harvested 48 hours afterward for protein extraction. Shown are immunoblot analyses of SHP2, cleaved (c)-CASP3, and BCL2. Each lane represents an individual NHLF sample. *Vertical black line* indicates that the lanes were run on two different gels. (*D*) Caspase-3/7 activity in NHLFs treated with the indicated plasmids for 48 hours. Data are normalized to caspase-3/7 activity (median absorbance) observed in R465M-treated cells. *Bars* and *error bars* represent mean ± SD activity of four NHLF samples (biological replicates). (*E*) Immunofluorescence analysis for terminal deoxynucleotidyltransferase dUTP nick end labeling (TUNEL)–positive cells after transfection with the indicated plasmids for 48 hours. Samples that were incubated with only the labeling solution were used as negative controls. (*F*) Quantitative scoring of TUNEL/DAPI (4′,6-diamidino-2-phenylindole) double-positive cells as a percentage of total DAPI-positive cells from four NHLF samples (biological replicates). Data represent means ± SD; one-way ANOVA, $*P < 0.05$. (*G*) SHP2 protein tyrosine phosphatase (PTP) activity in NHLFs transfected with the indicated plasmids for 48 hours. *Bars* and *error bars* represent mean ± SD (nmol/min) activity of two NHLF samples (biological replicates).

Reference

1. Tzouvelekis A, Yu G, Lino Cardenas CL, Herazo-Maya JD, Wang R, Woolard T, Zhang Y, Sakamoto K, Lee H, Yi J-S, Deluliis G, Xylourgidis N, Ahangari F, Lee PJ, Aidinis V, Herzog EL, Homer R, Bennet AM, Kaminski N. SH2 domain–containing phosphatase-2 is a novel antifibrotic regulator in pulmonary fibrosis. *Am J Respir Crit Care Med* 2017;195:500–514.

Copyright © 2020 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).